Trial Condition(s):

Diabetic Kidney Disease

A retrospective cohort study on treatment patterns and burden of disease using Japanese claims database in patient with Diabetic Kidney Disease

Bayer Identifier:

20011

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

The primary objective is to describe patient profile and health outcomes in DKD cohort and describe MRA treatment characteristics in a MRA sub-cohort. The secondary objective is to evaluate health care resource utilizations and costs in DKD cohort.

Inclusion Criteria
For DKD cohort:
                - Patients who have a claim with a diagnosis of DM (ICD-10: E10-E14) 
                - Patients with the evidence of CKD (eGFR less than 60 ml/min/1.73m2) during the study period 
                - Patients must have DM drugs during pre-index period or index month 

For MRA cohort:
              - Patients with a claim for a MRA drug during the study period any time after their DKD index date. Index date was defined as the first MRA prescription after their
DKD index date
Exclusion Criteria
For DKD cohort:
                - Patients who do not have at least 2 claims within the 1 year follow up period
                - Patients who do not have at least 1 claim within the 6 months pre-index period
                - Patients with a diagnosis of ESRD, PKD, or IGA within the pre-index period
For MRA cohort:
                - Patients who do not have at least 2 claims within the 1 year follow up period
                - Patients who do not have at least 1 claim within the pre-index period
                - Patients with a diagnosis of ESRD, PKD, or IGA within the pre-index period

Trial Summary

Enrollment Goal
19582
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Unspecified
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, Japan

Status
Completed

Trial Design